Filing Flows › Sight Sciences (SGHT) › Q3 2026
Sight Sciences (SGHT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Sight Sciences (SGHT) reported revenue of $24.9M for the third quarter 2026 (Q3 2026), +25% from a year earlier and +7% from the quarter before. Operating margin was -24.6%, net loss $6.8M (27.3% of revenue).
Sight Sciences, Q3 2026: revenue $24.9M (+25% year over year), operating margin -24.6%, net loss $6.8M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.9M | +7% | +25% |
| Operating profit | −$6.1M | — | — |
| Net earnings | −$6.8M | — | — |
| Operating cash flow | −$2.4M | — | — |
What changed
Revenue was $24.9M in Q3 2026, up 25% year over year and up 7% from the previous quarter. Surgical Glaucoma was the largest line at 84% of revenue. Dry Eye added $3.7M year over year (up 1962%), 74% of the total change.
Gross margin was 85.9%, down 0.4 points from Q3 2025. Operating costs exceeded revenue by $6.1M, an operating margin of -24.6%. Operating expenses grew 10% against revenue growth of 25%. The fastest-growing cost line was SG&A (+14%). The quarter ended with a net loss of $6.8M, wider than the previous quarter's $4.4M loss.
Operating cash flow was −$2.4M. Non-cash charges added back $110K of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items added $1.4M. Capital expenditures of $68K exceeded it, leaving free cash flow of −$2.5M.
Questions
What was Sight Sciences' revenue in the third quarter 2026?
Sight Sciences (SGHT) reported revenue of $24.9M for the third quarter 2026 (Q3 2026), +25% from a year earlier and +7% from the quarter before.
Was Sight Sciences profitable in the third quarter 2026?
Operating loss was $6.1M (-24.6% of revenue) and net loss $6.8M.
Source: Sight Sciences 10-Q on SEC EDGAR.